We are live on
!
Find out more
CM
Caption Management Portfolio holdings
AUM
$17.1B
1-Year Est. Return
70.99%
This Fund
S&P 500
This Quarter
Est. Return
+4.28%
1 Year Est. Return
+70.99%
3 Year Est. Return
+176.06%
5 Year Est. Return
+263.89%
10 Year Est. Return
–
AUM
$1.99B
AUM Growth
+$172M
(+9.5%)
Cap. Flow
+$156M
Cap. Flow
% of AUM
7.83%
Top 10 Holdings %
Top 10 Hldgs %
16.27%
Holding
935
New
395
Increased
92
Reduced
99
Closed
294
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
ONCE
Spark Therapeutics, Inc. Common Stock
ONCE
|
+$8.42M |
| 2 |
Marathon Petroleum
MPC
|
+$5.47M |
| 3 |
Liberty Global Class C
LBTYK
|
+$5.39M |
| 4 |
O'Reilly Automotive
ORLY
|
+$5.32M |
| 5 |
Crocs
CROX
|
+$5.07M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$12.6M |
| 2 |
Tapestry
TPR
|
+$12M |
| 3 |
iShares MSCI Saudi Arabia ETF
KSA
|
+$8.32M |
| 4 |
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
+$6.96M |
| 5 |
SAGE
Sage Therapeutics
SAGE
|
+$6.93M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 2.95% |
| 2 | Consumer Discretionary | 2.51% |
| 3 | Technology | 1.96% |
| 4 | Energy | 1.43% |
| 5 | Communication Services | 1.03% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
ETRN
301
CALL
DELISTED
Equitrans Midstream Corporation Common Stock
ETRN
| $1.5M | 0.08% |
+76,000
| New | +$1.58M |
|
|
LNW
302
DELISTED
Light & Wonder
LNW
| $1.49M | 0.07% |
75,000
+35,000
| +88% | +$724K |
|
303
PUT
T-Mobile US
TMUS
$185B
| $1.48M | 0.07% |
20,000
| – | – |
|
304
CALL
Dentsply Sirona
XRAY
$2.68B
| $1.46M | 0.07% |
+25,000
| New | +$1.34M |
|
|
305
PUT
Dentsply Sirona
XRAY
$2.68B
| $1.46M | 0.07% |
+25,000
| New | +$1.34M |
|
|
WW
306
PUT
DELISTED
WW International
WW
| $1.43M | 0.07% |
75,000
-35,400
| -32% | -$701K |
|
307
CALL
Acuity Brands
AYI
$9.83B
| $1.42M | 0.07% |
+10,300
| New | +$1.42M |
|
308
BioMarin Pharmaceuticals
BMRN
$11.6B
| $1.41M | 0.07% |
16,500
-6,100
| -27% | -$522K |
|
309
CALL
Banc of California
BANC
$3.03B
| $1.4M | 0.07% |
+100,000
| New | +$1.41M |
|
|
310
PUT
Banc of California
BANC
$3.03B
| $1.4M | 0.07% |
100,000
+90,000
| +900% | +$1.27M |
|
|
ESPR
311
PUT
DELISTED
Esperion Therapeutics
ESPR
| $1.4M | 0.07% |
+30,000
| New | +$1.41M |
|
|
P
312
Everpure Inc
P
$25.7B
| $1.39M | 0.07% |
+91,000
| New | +$1.78M |
|
313
Exelixis
EXEL
$13.3B
| $1.39M | 0.07% |
+65,000
| New | +$1.36M |
|
314
PUT
RadNet
RDNT
$5.02B
| $1.38M | 0.07% |
+100,000
| New | +$1.28M |
|
|
WLH
315
PUT
DELISTED
WILLIAM LYON HOMES
WLH
| $1.37M | 0.07% |
+75,000
| New | +$1.35M |
|
|
ESV
316
CALL
DELISTED
Ensco Rowan plc
ESV
| $1.36M | 0.07% |
+160,000
| New | +$1.85M |
|
|
BBBY
317
CALL
Bed Bath & Beyond
BBBY
$481M
| $1.36M | 0.07% |
+133,100
| New | +$1.24M |
|
|
ZEN
318
DELISTED
ZENDESK INC
ZEN
| $1.34M | 0.07% |
+15,000
| New | +$1.29M |
|
|
ITCI
319
PUT
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| $1.33M | 0.07% |
102,300
+62,300
| +156% | +$799K |
|
|
MNK
320
DELISTED
MALLINCKRODT PUBLIC LIMITED COMPANY
MNK
| $1.32M | 0.07% |
+144,000
| New | +$2.08M |
|
321
CALL
Aurinia Pharmaceuticals
AUPH
$1.91B
| $1.32M | 0.07% |
200,000
+50,000
| +33% | +$319K |
|
322
CALL
PDF Solutions
PDFS
$1.93B
| $1.31M | 0.07% |
+100,000
| New | +$1.28M |
|
323
Theravance Biopharma
TBPH
$874M
| $1.31M | 0.07% |
80,000
+67,500
| +540% | +$1.37M |
|
324
Nexstar Media Group
NXST
$5.82B
| $1.3M | 0.07% |
+12,900
| New | +$1.39M |
|
325
Principal Financial Group
PFG
$24.3B
| $1.3M | 0.07% |
+22,500
| New | +$1.24M |
|
Similar funds
ASRS
PP
VMPIC
BCIM
BBA
FCM
AIMCA
Caption Management's Q2 2019 Portfolio in Review
As of Q2 2019, Caption Management held 935 positions worth $1.99B, up 9.5% from $1.81B the previous quarter. Its ten largest holdings account for 16% of the portfolio.
Caption Management deployed $156M of net new capital in Q2 2019, opening 395 new positions and adding to 92 existing holdings. Its largest new stake was Spark Therapeutics, Inc. Common Stock: 78,000 shares worth $7.99M.
By sector, the portfolio is most concentrated in Healthcare at 3% of assets, down from 3.9% a quarter earlier, followed by Consumer Discretionary and Technology.
On the sell side, the largest reduction was Bristol-Myers Squibb, an estimated $12.6M trimmed.
- Caption Management's largest Q2 2019 buy was Spark Therapeutics, Inc. Common Stock: 78,000 shares worth $7.99M.
- Caption Management added most to Crocs in Q2 2019, an estimated $5.07M increase.
- Caption Management's biggest Q2 2019 reduction was Bristol-Myers Squibb, cutting an estimated $12.6M.
- Caption Management fully exited iShares MSCI Saudi Arabia ETF in Q2 2019, selling an estimated $8.32M.
- Caption Management's ten largest holdings make up 16% of its $1.99B portfolio in Q2 2019.
- Caption Management opened 395 new positions and closed 294 in Q2 2019.
- Caption Management's portfolio value rose 9.5% quarter-over-quarter to $1.99B.
Based on Caption Management's 13F filing for Q2 2019, filed 13 Aug 2019.